Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock
Humanigen, Inc. (Nasdaq:HGEN) has priced its public offering of 5,000,000 shares of common stock at $18.50 each, raising approximately $92.5 million before deductions. The offering is expected to close around April 5, 2021, with an option for underwriters to purchase an additional 750,000 shares. Proceeds will be used for manufacturing and commercial preparation for the COVID-19 treatment lenzilumab™, pending FDA Emergency Use Authorization, along with general corporate purposes.
- Raised approximately $92.5 million in gross proceeds.
- Proceeds aimed for manufacturing and commercialization of lenzilumab™ for COVID-19 treatment.
- Potential FDA Emergency Use Authorization could boost product adoption.
- Dilution risk for existing shareholders due to the new share offering.
- Market uncertainty surrounding the effectiveness and approval timeline of lenzilumab™.
Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of
Jefferies, Credit Suisse and Cantor are acting as joint book-running managers for the offering. Bryan, Garnier & Co. is acting as European lead manager for the offering, Oppenheimer & Co. is acting as lead manager for the offering and H.C. Wainwright & Co., National Securities Corporation and Roth Capital Partners are acting as co-managers for the offering.
Humanigen intends to use the net proceeds from the offering for manufacturing and commercial preparation in the event of receipt of an Emergency Use Authorization from the Food and Drug Administration for lenzilumab™ in hospitalized COVID-19 patients, as well as for working capital and other general corporate purposes.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission (the “SEC”). The securities will be offered only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at prospectus_department@jefferies.com or by telephone at (877) 821-7388; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27650, by email at usa.prospectus@credit-suisse.com or by telephone at (800) 221-1037; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements. Examples of forward-looking statements in this release include, without limitation, statements regarding the timing for completing the offering, and the amount and contemplated use of proceeds from the offering. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the various risks and uncertainties described in the “Risk Factors” sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330006129/en/
FAQ
What is the purpose of Humanigen's share offering?
How much has Humanigen raised in its public offering?
What is the offering price for Humanigen's shares?
When is the expected closing date for the offering?
What are the risks associated with Humanigen's public offering?
